High-Yield ETFs vs Total Return - Comparing JEPQ, AMLP, and AbbVie

TL;DR

• JEPQ delivers a 10.3% yield while actually defending its share price — a rarity among high-income ETFs
• AMLP combines a 7.9% yield with a 72% price return through energy infrastructure MLPs
• AbbVie (ABBV) offers a 3% yield on top of a stock price that has doubled in 5 years, making it the total return champion

The Temptation and Reality of High Yield

If you want to live off your dividends, you need high yields. But when you see funds promising 40-60% dividend yields, you should be skeptical. Behind many sky-high yields lies a stock price in free fall.

From my analysis, succeeding in high-yield investing requires looking at both the yield and the price defense. And there are options that deliver on both fronts.

JEPQ: The 10.3% Yielder That Actually Protects Your Capital

The JP Morgan NASDAQ Premium Income ETF (JEPQ) offers a 10.3% dividend yield. What makes it exceptional is that it delivers this high income without destroying the share price.

ETF/Stock	Dividend Yield	5-Year Price Return	Holdings	Key Feature
JEPQ	10.3%	Positive (double-digit)	108 stocks	Covered call, low fees
QYLD	~12%	-20%	NASDAQ 100	Price erosion
SDIV	~11%	Major loss	Global	Price crash
AMLP	7.9%	+72%	13 MLPs	Energy infrastructure
ABBV	3%	+100% (doubled)	Single stock	Pharma total return

Other high-income ETFs like QYLD and SDIV paid attractive dividends but lost 20%+ on share price, eating into total returns. JEPQ holds 108 NASDAQ 100 stocks, generates income through a covered call strategy, and charges just 0.35% in fees — lower than most competitors.

Tech stocks make up 41% of JEPQ's portfolio, with communication services at 12%. You get exposure to growth names like Nvidia, Apple, and Microsoft alongside defensive holdings like Walmart, Pepsi, and Costco — blending growth potential with stability.

AMLP: 7.9% Yield Plus 72% Price Appreciation from Energy Infrastructure

For investors wanting both high cash flow and price growth, the Alerian MLP ETF (AMLP) delivers with a 7.9% yield and a 72% price return over five years.

AMLP invests in 13 master limited partnerships that own energy infrastructure — pipelines, storage, and processing facilities across the United States. The key advantage is that these MLPs charge volume-based fees rather than depending on oil prices, creating stable cash flows regardless of commodity price swings. A special tax structure that passes profits directly to shareholders enables the higher yield.

AbbVie: The Total Return King - 3% Yield Plus Doubled Share Price

My preferred dividend strategy is total return — maximizing the combination of dividend yield and price appreciation. And in this category, AbbVie (ABBV) is hard to beat.

A 3% dividend yield paired with a stock price that has nearly doubled in five years. This $410 billion pharmaceutical powerhouse holds durable advantages in immunology, oncology, and neuroscience.

AbbVie's Growth Catalysts:

• Transitioning from legacy blockbuster Humira to higher-growth Skyrizi and Rinvoq
• Skyrizi and Rinvoq projected to generate over $31 billion in sales by 2027
• Rinvoq exclusivity extended to 2037
• Analysts forecast 38% earnings increase over the next year

AbbVie is also a Dividend Aristocrat, having raised its dividend for 25+ consecutive years. You get reliable income growth combined with meaningful capital appreciation.

Investment Takeaways

• For immediate bill-paying income, JEPQ (10.3%) and AMLP (7.9%) are strong high-yield ETF options
• ETFs provide safer diversification compared to individual high-yield stocks
• For long-term wealth building, reinvesting dividends in total return stocks like AbbVie is optimal
• When chasing high yields, always verify the 5-year price return alongside the dividend

FAQ

Q: What is JEPQ's covered call strategy? A: JEPQ sells call options on its holdings to collect premium income. This sacrifices some upside potential in exchange for steady monthly income. It's why JEPQ can pay 10%+ yields while defending its share price — a balance most competitors fail to achieve.

Q: What are the tax benefits of MLP ETFs like AMLP? A: MLPs use a partnership structure that avoids corporate taxation, passing profits directly to investors. This enables higher dividend yields than traditional corporations. Investing through the ETF simplifies tax filing compared to holding MLPs directly.

Q: Isn't Humira's patent expiration a risk for AbbVie? A: This risk is already priced in. AbbVie is successfully transitioning to Skyrizi and Rinvoq, which are projected to generate over $31 billion in revenue by 2027. Rinvoq's exclusivity extends to 2037, ensuring stable long-term cash flows.

Q: Should I choose high-yield ETFs or dividend growth stocks? A: It depends on your goal. If you need maximum cash flow today, high-yield ETFs like JEPQ are ideal. For building wealth over 5-10+ years, reinvesting dividends in growth-oriented names like AbbVie or AFLAC delivers superior total returns.